MDACC Study No:2013-0302 ( NCT No: NCT01829711)
Title:A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Moxetumomab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if moxetumomab pasudotox
can help to control HCL. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Moxetumomab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:MedImmune
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults